50th Annual Meeting of the American Society of Hematology

Activity: Other


White DL, Saunders VA, Dang P, Frede A, Eadie LN, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim D-W, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, Hughes T.
CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study.
Poster Presentation
San Francisco, California
Period6 Dec 20089 Dec 2008